GoggleDocs

🥽🩺Docs/nurses/pharmacists from U.K. Talking CardioRenoMetabolic & more Catch us on YouTube |Educate, Motivate, Activate!

[Don McGowan @donmcgowan]

Dear @Ofcom

Please can you clarify to the nation why this is allowed under your current broadcasting rules?

A sitting MP [sometimes] on a TV channel he part owns, delivering a party political broadcast on behalf of Reform UK?

Seriously ... WTF?

[Patrick Holmes @drpatrickholmes]

🆕NICE guidelines

Arguably the biggest shift in #type2diabetes care in over a decade.

Phenotype first. HbA1c second.

@drkevinfernando & I are running a free hour on what it actually changes in clinic.

Thu 10 Sept, 7-8pm BST

No industry funding

🔗https://t.co/hkZ3HZwPzv

[Dr Amar Puttanna 🎸 @AmarPut]

Excited to work with @ATTDconf

👉🏽Management of older adults, technology & diabetes👈🏽

❓How do we manage older adults with diabetes
❓How do we balance intervention with support and QOL
❓What is the role of technology & how can we simplify/facilitate

https://t.co/Twp9ju8U4B

[GoggleDocs @GoggleDocs]

@scivier_martin @AmarPut @ATTDconf @EASDnews @AmDiabetesAssn @ABCDiab @IntDiabetesFed @dramitaol @AliceYYCheng @JGolding_1 @AskDrShashank @banshisaboo It’s a webinar I believe

[Brendon Neuen @brendonneuen]

“CKD is not really a disease… trials don’t necessarily translate to living longer”

Not really sure where to start here. But trials in the last 20 years in which CKD therapies extend survival:

#DAPACKD HR 0.69 (0.53-0.88)
#FIDELITY HR 0.89 (0.79-1.00)
#FLOW HR 0.80 (0.67-0.95)

[GoggleDocs @GoggleDocs]

#ESCcongress2025

💊 STAREE in NEJM: atorvastatin 40mg vs placebo, 9,971 adults aged 70+, 5.9 yrs

📉 Major CV events HR 0.70 ✅ NNT 37
⚖️ Disability-free survival HR 0.94 (0.84–1.05) ❌
📊 CV death HR 1.00

Fewer heart attacks. Not a longer or more independent life

[Ketan Dhatariya @ketandhatariya]

Interviewed by the @NakedScientists on diabetes related foot wounds @Franers13 @iwgdf @gooday_c https://t.co/rPdmWtIzIq

[GoggleDocs @GoggleDocs]

💊 The 82-year-old on a statin since their 60s. No ASCVD, no symptoms, no evidence either way

SAGA/SITE finally randomised it 🔬

📊 3-yr mortality 7.9% continue vs 7.2% stop
✅ Non-inferior (−0.68%, CI −3.95 to 2.60)
❗ No QoL gain from stopping

Shared decision, not a rule

🔗https://t.co/UFQBaL6OhF

[Partha S Kar 🇮🇳🇬🇧🏏🎥 @parthaskar]

#Obesity care in the #NHS is an absolute and utter shambles

Why don’t we just be honest and say we can’t afford any of the drugs till they go generic?

Saves lot of people angst.

And less said the better about improving conditions to tackle core issues of obesity

Either needs new leadership or we need to park it in the “impossible” box and focus on other areas.

[Partha S Kar 🇮🇳🇬🇧🏏🎥 @parthaskar]

Primary Care

The bedrock of #NHS work

And this is why I say that primary care leadership has failed within @NHSEngland in the decade or so NHSE has existed

If you haven't been able to make the case for increased funding in THE area which does need that?

I am afraid the outcomes follow the consequences of your inability to negotiate the funds.

So- we are here- where we are.

Leadership inactions or failures in a healthcare setting- always has consequences

Perhaps never for the individual- yet always for the population.

( Data via @HealthFdn )

[Kevin Fernando @drkevinfernando]

🔥UK first in Europe to authorise #orforglipron for weight management & #T2D🔥
🎯Orforglipron is a small-molecule, non-peptide oral #GLP1RA
See my @Medscape commentary piece on the ACHIEVE-1 trial from #ADA2025 for more background info - link in comments 👇🏾

[Kevin Fernando @drkevinfernando]

🔥Our @Medscape Primary Care #Hack on "Identification & Holistic Management of #CKD in Primary Care" has been updated for 2026!

🙏Thanks to my co-authors @EimearDarcy & Will Hinchliffe

PDF download in comments 👇

[Partha S Kar 🇮🇳🇬🇧🏏🎥 @parthaskar]

The national work in #Diabetes continues - as it must.

To draw attention to: @NHSGIRFT report -
Diabetes: Children & Young Adults #T1D #T2D

Thank you @DrDita @SaimeFulya for the amazing work in ages 0-18
My area of interest ages 19-25

Relevance of transition services, tackling inequity, better or priority access - and a key group in BOTH types of #Diabetes - given the impact of a life long condition

@NHSEngland @DHSCgovuk @pcdosociety @DiabetesUK @BT1DUK

Read, share and use as appropriate

https://t.co/kZGSbAOvos

[GoggleDocs @GoggleDocs]

🚨 Obicetrapib gets a positive CHMP opinion 🎉

@EMA_News

👉 A new lipid⤵️ 🔧

Oral once-daily CETP inhibitor:
🟢 LDL-C ↓33% (↓49% + ezetimibe)
🟢 Lp(a), ApoB & non-HDL all ↓

⚠️ No CVOT yet, so lipid-lowering only 'til PREVAIL. A 4th-line option to hit targets?

#CKM #CVRM

🔗https://t.co/3HBZKpyjhB

[Partha S Kar 🇮🇳🇬🇧🏏🎥 @parthaskar]

September 2023.

That’s when I started calling this all out re PAs

And amidst all of this?

The gall to accuse Gill Leng of bias- and then shut down by a legal court?

Is something incredible.

Threatening anyone who didn’t agree with their leaders views; Accusations of bias; Personal attacks; Referrals to GMC…

Everything has been tried.

And here we are.

I may not know much about workforce - but I know that anyone in healthcare working outside their training?

Will cause harm.

Implement the Leng recommendations.
Enough obfuscation done.

@DHSCgovuk @NHSEngland @NHSE_WTE

[Prof Derek Connolly @DrDerekConnolly]

https://t.co/mCjxVO94Up
@PCCS_UK @BritishCardioSo @ESC_Journals @bacpr @AtrialFibUK @ProfKausikRay @cpgale3 @DrRaniKhatib @GoggleDocs

[Dr Amar Puttanna 🎸 @AmarPut]

Great to see NICE approval for Teplizumab! Know firsthand the hard work behind the scenes to get to this. A new era in T1D care 🙌🏽

Await the full NICE TA being available soon

First drug to delay onset of type 1 diabetes made available on NHS

https://t.co/qhJEQT2g2R

[GoggleDocs @GoggleDocs]

What does metformin actually add in prediabetes beyond delaying diabetes❓

JAMA, 21-yr DPP/DPPOS follow-up (n=1,173):
🔹 Lifestyle reduced multimorbidity (≥2 long-term conditions): HR 0.79
🔸 Metformin did not: HR 0.91 (NS)
🔹 High-cost dyads: lifestyle HR 0.57. Metformin no signal

Layered on: no CV, mortality, cancer or frailty signal for metformin in prediabetes. Lifestyle has hard outcome data in Da Qing (CV events, mortality, +1.44 yr life expectancy).

And "lifestyle" here isn't a pamphlet. DPP was 16 individual sessions, 2 yr of monthly follow-up, structured ≥7% weight loss, ≥150 min/wk activity. Not soft.

The clinical question shifts:
👉Less "should we start metformin?"
👉More "what structured support gives this person the best chance over the next 20 years?"
🔗 https://t.co/7ChAxPPyNA

[Dr Amar Puttanna 🎸 @AmarPut]

Great to be @mimslearning Live speaking on Obesity in an enjoyable panel discussion with @drpatrickholmes and going solo talking about multiple risk factor management and cardio-reno-metabolic care in primary and secondary care 🤓